Results 51 to 60 of about 13,217 (287)

Utility of quantitative standardized uptake value from pre-operative bone SPECT/CT for predicting post-surgical MRONJ healing response

EJNMMI Research
Background Medication-related osteonecrosis of the jaw (MRONJ) is a challenging condition often associated with long-term use of anti-resorptive medications.
Jung-Hyun Park, Da-Mi Yoon, Hai-Jeon Yoon, Jin-Woo Kim   +3 more
doaj   +1 more source

2D copper nanozyme patches facilitate bone regeneration via interfacial modulation of osteoclast‐osteoblast dynamics

BMEMat, EarlyView.
This study develops a nano‐enzyme patch (ezPatch) targeting bone interfaces. Utilizing ligand‐to‐metal charge transfer (LMCT) catalysis and bone‐targeting ligands on copper nanosheets, ezPatch simultaneously scavenges reactive oxygen species (ROS) and generates oxygen in situ at bone‐losing sites.
Yi Chen, Haoyue Hu, Danyang Wang, Ying Wang, Zhibang Li, Xiaoyi Liu, Yandi Zhang, Junkun Feng, Weiwei Zhao, Kai Li, Qi‐Zhi Zhong, Shaohua Ge, Jianhua Li   +12 more
wiley   +1 more source

Topical erythropoietin as a novel preventive and therapeutic agent in bisphosphonate-related osteonecrosis of the jaw

Dental Hypotheses, 2016
Introduction: One of the most common side effects of bisphosphonate intake is osteonecrosis of the jaw (ONJ) which may develop following dentoalveolar interventions.
Pantea Nazeman, Maryam Rezai Rad, Arash Khojasteh   +2 more
doaj   +1 more source

Management of severe bone loss in patients at risk of medication‐related osteonecrosis of the jaw with microsurgery and guided bone regeneration: A case study

Clinical Advances in Periodontics, EarlyView.
Abstract Background Medication‐related osteonecrosis of the jaw (MRONJ) is a challenging complication associated with antiresorptive medications. Its exact pathophysiology remains unclear, but dental extractions and infections are known triggers, complicating prevention, and treatment.
Pedro Franco Ferreira, José Maurício Paradella de Camargo, Lara Maria Alencar Ramos Innocentini, Ana Carolina Fragoso Motta   +3 more
wiley   +1 more source

Investigation of clindamycin concentrations in human plasma and jawbone tissue in patients with osteonecrosis of the jaw: A prospective trial.

Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
The aim of this study was to investigate the jawbone concentration of clindamycin (CLI) in patients with an osteonecrosis of the jaw (ONJ). Patients with medication-related ONJ (MRONJ) and osteoradionecrosis (ORN) with an antibiotic treatment with CLI ...
Anton Straub, Maximilian Stapf, Roman C. Brands, A. Kübler, Thiên-Trí Lâm, Andreas Vollmer, Sebastian Gubik, Oliver Scherf-Clavel, Stefan Hartmann   +8 more
semanticscholar   +1 more source

The Use of Photodynamic Therapy on Medication-Related Osteonecrosis of the Jaws: Animal Study

Balkan Journal of Dental Medicine, 2021
Background/Aim: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) was first introduced in 2003 and its scope was expanded by the name medication-related osteonecrosis of the jaw (MRONJ), since 2014.
Karapinar Gökay, Zincir Özge Özdal, Ünür Meral, Olgaç Necat Vakur   +3 more
doaj   +1 more source

Jaw osteonecrosis in patients treated with denosumab 120 mg with regular dental monitoring: 4-year retrospective study

Journal of Oral Medicine and Oral Surgery, 2021
Background: Medication-related osteonecrosis of the jaw (MRONJ) is an expected, but rare adverse effect of denosumab. There are few data denosumab 120 mg related MRONJ occurrence when regular dental monitoring is planned.
Beaudouin Sophie, Scailteux Lucie-Marie, Lefeuvre Claudia, Gamby Romain, Cairon-Lejeune Sophie   +4 more
doaj   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

Estradiol replacement attenuates alendronate‐associated adverse effects on alveolar bone repair in ovariectomized rats

Journal of Periodontology, EarlyView.
Abstract Background Sodium alendronate (ALN) is widely used to treat postmenopausal osteoporosis, but both estrogen deficiency and antiresorptive therapy may impair alveolar bone repair after tooth extraction. A clinically relevant but insufficiently explored scenario involves estrogen‐deficient individuals receiving hormone replacement therapy (HRT ...
Pedro H. C. Isaias, Paulo G. B. Silva, Isabelly V. do Nascimento, Raul A. D. A. da Silva, Thayla M. do C. Sousa, Ana J. A. de de Vasconcelos, José V. M. Lemos, Fabrício B. Sousa, Ana P. N. N. Alves, Mário R. L. Mota   +9 more
wiley   +1 more source

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis

, 2010
Bisphosphonates are the leading drugs for the treatment of osteoporosis. In ­randomized controlled trials (RCTs), alendronate, risedronate, and zoledronate have shown to reduce the risk of vertebral, nonvertebral, and hip fractures, whereas RCTs with ...
Graham Russell, Cooper, Cyrus, Ebetino, F. Hal, Cooper, C, Russell, RG, Pazianas, Michael, Ebetino, FH, Russell, R. Graham G., Pazianas, M   +8 more
core   +1 more source